Anti-EGFR-immunoliposomes loaded with doxorubicin in patients with advanced triple negative EGFR positive breast cancer - A multicenter single arm phase II trial « Etude SAKK24/14 » Sponsor : SAKK CONTACTS AUX HUG : Investigateur responsable: Dr Alexandre Bodmer, 079 55 32 405 DESIGN DE L’ETUDE : OBJECTIF DE L’ETUDE Cette étude a pour but de déterminer l’efficacité de l’anti-EGFR-IL-dox en première ligne chez des patients atteints d’un cancer du sein triple négatif et EGFR positif. Un autre objectif est d’investiguer la sélection clonale sous ce traitement anti-EGFR-IL-dox qui pourrait aboutir au développement d’une résistance au traitement. Pour ce faire des prélèvements de sangs seront effectués à des temps précis au cours de l’étude. CRITERES D’INCLUSION / EXCLUSION : Main Inclusion criteria: Metastatic or locally advanced non operable TNBC EGFR expression of at least (1+) in immunohistochemistry Measurable or evaluable disease No prior systemic treatment for metastatic or inoperable disease WHO PS of 0-2 Patient ≥ 18 years Main Exclusion criteria: Evidence of CNS or leptomeningeal metastases (even if previously treated) History of hematologic or primary solid tumor malignancy, unless in remission for at least 5 years. Inclusion of adequately treated cervical carcinoma in situ or localized non-melanoma skin cancer is permitted Previous therapy with more than 240 mg/m2 of doxorubicin or more than 450 mg/m2 of epirubicin SAKK 24/14 - Anti-EGFR-IL-dox Trial summary, version 1.0, 10.05.2016 Page 2 of 6 Previous radiotherapy for the metastatic disease (palliative radiotherapy of only non-target lesions is allowed) Etude SAKK 24/14 befy 06.12.2016 Adjuvant treatment must have been stopped at least 6 months before registration Breastfeeding Any other serious underlying medical, psychiatric, psychological, familial or geographical condition, which in the judgment of the investigator may interfere with the planned staging, treatment and follow-up, affect patient compliance or place the patient at high risk from treatment-related complications. Etude SAKK 24/14 befy 06.12.2016